Alnylam and regeneron report positive interim phase 1 clinical data on aln-app, an investigational rnai therapeutic for alzheimer's disease and cerebral amyloid angiopathy

Cambridge, mass. & tarrytown, n.y.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny) and regeneron pharmaceuticals, inc. (nasdaq: regn) announced today positive interim results from the ongoing single ascending dose part of the phase 1 study of aln-app, an investigational rnai therapeutic targeting amyloid precursor protein (app) in development for the treatment of alzheimer's disease and cerebral amyloid angiopathy (caa). twenty patients have been enrolled in three single-dose coh.
REGN Ratings Summary
REGN Quant Ranking